Management of Hepatitis C Infection
Summary
- High SVR rates with 12 weeks of elbasvir/grazoprevir in treatment-naive patients with genotypes 1, 4, 5, or 6 HCV infection
- C-EDGE-TN: SVR12 rate 95% in patients with genotype 1, 4, or 6 HCV infection[Zeuzem 2015]
- C-SCAPE: better efficacy of elbasvir/grazoprevir regimen with vs without ribavirin in noncirrhotic patients with genotype 5 HCV infection, with comparable efficacy in genotype 6 HCV infection[Brown 2018]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C-Treatment